نتایج جستجو برای: tp53 mutation and expression

تعداد نتایج: 16973495  

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2013
F Ganci A Sacconi N Bossel Ben-Moshe V Manciocco I Sperduti L Strigari R Covello M Benevolo E Pescarmona E Domany P Muti S Strano G Spriano G Fontemaggi G Blandino

BACKGROUND TP53 mutation is associated with decreased survival rate in head and neck squamous cell carcinoma (HNSCC) patients. We set out to identify microRNAs (miRNAs) whose expression associates with TP53 mutation and survival in HNSCC. PATIENTS AND METHODS We analyzed TP53 status by direct sequencing of exons 2 through 11 of a prospective series of 121 HNSCC samples and assessed its associ...

2018
Haruna Furukawa Tomoki Makino Makoto Yamasaki Koji Tanaka Yasuhiro Miyazaki Tsuyoshi Takahashi Yukinori Kurokawa Kiyokazu Nakajima Shuji Takiguchi Masaki Mori Yuichiro Doki

TP53 is associated with the resistance of cytotoxic treatment and patient prognosis, and the mutation rate of TP53 in esophageal squamous cell carcinoma (ESCC) is extraordinarily high, at over 90%. PRIMA-1 (p53 re-activation and induction of massive apoptosis) has recently been reported to restore the function of mutant TP53; however, its antitumor effect and mechanism in ESCC remain unclear. A...

M.A Damghani M.R Bazrafshani T,R Mirshekari

Background &Aims: Laryngeal cancer is the second common cancer of respiratory tract, following the lung cancer. Carcinogenesis is a complex multistage process; molecular genetics has provided the evidence that activation of proto-oncogene and loss or inactivation of tumor suppressor genes (TSG) are involved in a large number of malignancies. One of the earliest significant tumor suppressor gene...

2013
Frédérique Végran Magali Rebucci Sandy Chevrier Muriel Cadouot Romain Boidot Sarab Lizard-Nacol

The presence of a TP53 gene mutation can influence tumour response to some treatments, especially in breast cancer. In this study, we analysed p53 mRNA expression, LOH at 17p13 and TP53 mutations from exons 2 to 11 in 206 patients with breast carcinoma and correlated the results with disease-free and overall survival. The observed mutations were classified according to their type and location i...

2016
Hajnalka Harami-Papp Lőrinc S. Pongor Gyöngyi Munkácsy Gergő Horváth Ádám M. Nagy Attila Ambrus Péter Hauser András Szabó László Tretter Balázs Győrffy

Promising new hallmarks of cancer is alteration of energy metabolism that involves molecular mechanisms shifting cancer cells to aerobe glycolysis. Our goal was to evaluate the correlation between mutation in the commonly mutated tumor suppressor gene TP53 and metabolism. We established a database comprising mutation and RNA-seq expression data of the TCGA repository and performed receiver oper...

2016
Alexander J. Cole Trisha Dwight Anthony J. Gill Kristie-Ann Dickson Ying Zhu Adele Clarkson Gregory B. Gard Jayne Maidens Susan Valmadre Roderick Clifton-Bligh Deborah J. Marsh

The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian cancer (HGSOC). Mutations cause loss of wild-type p53 function due to either gain of abnormal function of mutant p53 (mutp53), or absent to low mutp53. Massively parallel sequencing (MPS) enables increased accuracy of detection of somatic variants in heterogeneous tumours. We used MPS and immunohisto...

2013
Angeles Alvarez Secord Marcus Q. Bernardini Gloria Broadwater Lisa A. Grace Zhiqing Huang Tsukasa Baba Eiji Kondoh Gregory Sfakianos Laura J. Havrilesky Susan K. Murphy

OBJECTIVES To elucidate the association between thrombospondin1 (THBS1) expression and TP53 status and THBS1 promoter methylation in epithelial ovarian cancer (EOC). METHODS Epithelial ovarian cancer cell lines with known TP53 status were analyzed for THBS1 gene expression using Affymetrix U133 microarrays and promoter methylation by pyrosequencing. THBS1 mRNA expression was obtained pre- and...

2016
Balázs Murnyák Tibor Hortobágyi

Despite controversy on the correlation between p53 accumulation and TP53 mutational status, immunohistochemical (IHC) detection of overexpressed protein has long been used as a surrogate method for mutation analysis. The aim of our study was to characterise the IHC expression features of TP53 somatic mutations and define their occurrence in human cancers. A large-scale database analysis was con...

2016
Gilles Gadea Nikola Arsic Kenneth Fernandes Alexandra Diot Sébastien M Joruiz Samer Abdallah Valerie Meuray Stéphanie Vinot Christelle Anguille Judit Remenyi Marie P Khoury Philip R Quinlan Colin A Purdie Lee B Jordan Frances V Fuller-Pace Marion de Toledo Maïlys Cren Alastair M Thompson Jean-Christophe Bourdon Pierre Roux

TP53 is conventionally thought to prevent cancer formation and progression to metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation status does not accurately predict cancer progression. Here we report, based on clinical analysis corroborated with experimental data, that the p53 isoform Δ133p53β promotes cancer cell invasion, regardless of TP53 mutatio...

2012
Ruth L. Vinall Jane Q. Chen Neil E. Hubbard Shola S. Sulaimon Michael M. Shen Ralph W. DeVere White Alexander D. Borowsky

Tp53 mutations are common in human prostate cancer (CaP), occurring with a frequency of ∼30% and ∼70% in localized and metastatic disease, respectively. In vitro studies have determined several common mutations of Tp53 that have specific gain-of-function properties in addition to loss of function, including the ability to promote castration-resistant (CR) growth of CaP cells in some contexts. T...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید